Share this video  

ASCO 2021 | The IMMULAB trial: pembrolizumab with local ablation for patients with early-stage HCC

Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the IMMULAB study (NCT03753659), a trial-in-progress evaluating immunotherapy with pembrolizumab in combination with local ablation for patients with early-stage hepatocellular carcinoma (HCC). This investigation will evaluate the clinical activity of peri-interventional treatment with the anti-PD1 antibody pembrolizumab in HCC patients who are candidates for local ablation. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Arndt Vogel, MD has had a speaker, consultancy and advisory role at Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, and Terumo.